NASDAQ:FMTX Forma Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Forma Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $7.03 -0.21 (-2.90%) (As of 06/24/2022 04:00 PM ET) Add Compare Share Today's Range$6.72▼$7.4550-Day Range$5.10▼$8.3852-Week Range$4.95▼$26.61Volume1.29 million shsAverage Volume593,244 shsMarket Capitalization$336.07 millionP/E RatioN/ADividend YieldN/APrice Target$45.20 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive FMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Forma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FMTX Stock Forecast (MarketRank)Overall MarketRank™1.93 out of 5 starsMedical Sector663rd out of 1,418 stocksBiological Products, Except Diagnostic Industry105th out of 216 stocksAnalyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingForma Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $45.20, Forma Therapeutics has a forecasted upside of 543.0% from its current price of $7.03.Amount of Analyst CoverageForma Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.9 Community Rank Outperform VotesForma Therapeutics has received 30 “outperform” votes. (Add your “outperform” vote.)Underperform VotesForma Therapeutics has received 21 “underperform” votes. (Add your “underperform” vote.)Community SentimentForma Therapeutics has received 58.82% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Forma Therapeutics and other stocks. Vote “Outperform” if you believe FMTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FMTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldForma Therapeutics does not currently pay a dividend.Dividend GrowthForma Therapeutics does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Forma Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.79% of the stock of Forma Therapeutics is held by insiders.Percentage Held by Institutions87.22% of the stock of Forma Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Forma Therapeutics are expected to decrease in the coming year, from ($3.88) to ($3.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Forma Therapeutics is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Forma Therapeutics is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioForma Therapeutics has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Forma Therapeutics (NASDAQ:FMTX)Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.Read More FMTX Stock News HeadlinesJune 22, 2022 | finance.yahoo.comCan Forma Therapeutics Holdings, Inc. (FMTX) Climb 536% to Reach the Level Wall Street Analysts Expect?June 16, 2022 | americanbankingnews.comResearch Analysts Set Expectations for Forma Therapeutics Holdings, Inc.'s FY2022 Earnings (NASDAQ:FMTX)June 15, 2022 | finance.yahoo.comBears are Losing Control Over Forma Therapeutics Holdings, Inc. (FMTX), Here's Why It's a 'Buy' NowJune 13, 2022 | finance.yahoo.comRead Why Forma Therapeutics' Current Price Level Is 'Attractive Entry Point'June 9, 2022 | americanbankingnews.comCantor Fitzgerald Comments on Forma Therapeutics Holdings, Inc.'s FY2023 Earnings (NASDAQ:FMTX)June 3, 2022 | finance.yahoo.comForma Therapeutics to Present at the Jefferies Healthcare ConferenceMay 31, 2022 | americanbankingnews.comForma Therapeutics (NASDAQ:FMTX) Upgraded by Zacks Investment Research to "Buy"May 30, 2022 | americanbankingnews.comForma Therapeutics (NASDAQ:FMTX) PT Lowered to $46.00 at OppenheimerMay 30, 2022 | americanbankingnews.comSVB Leerink Trims Forma Therapeutics (NASDAQ:FMTX) Target Price to $23.00May 26, 2022 | finance.yahoo.comForma Therapeutics Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline at Inaugural Research and Development (R&D) DayMay 8, 2022 | finance.yahoo.comCompanies Like Forma Therapeutics Holdings (NASDAQ:FMTX) Are In A Position To Invest In GrowthMay 6, 2022 | seekingalpha.comForma Therapeutics Holdings Inc. (FMTX) CEO Frank Lee on Q1 2022 Results - Earnings Call TranscriptMay 6, 2022 | investing.comForma Therapeutics Holdings Tops Q1 EPS by 12cSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FMTX CUSIPN/A CIK1538927 Webwww.formatherapeutics.com Phone617-679-1970FaxN/AEmployees166Year FoundedN/ACompany Calendar Last Earnings5/06/2022Today6/24/2022Next Earnings (Estimated)8/12/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$45.20 High Stock Price Forecast$58.00 Low Stock Price Forecast$23.00 Forecasted Upside/Downside+543.0%Consensus RatingBuy Rating Score (0-4)3 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.820010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-172.96 million Net MarginsN/A Pretax MarginN/A Return on Equity-34.81% Return on Assets-31.63% Debt Debt-to-Equity RatioN/A Current Ratio16.95 Quick Ratio16.95 Sales & Book Value Annual Sales$100.56 million Price / Sales3.34 Cash FlowN/A Price / Cash FlowN/A Book Value$10.51 per share Price / Book0.67Miscellaneous Outstanding Shares47,805,000Free Float45,037,000Market Cap$336.07 million OptionableNot Optionable Beta0.44 Forma Therapeutics Frequently Asked Questions Should I buy or sell Forma Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Forma Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Forma Therapeutics stock. View analyst ratings for Forma Therapeutics or view top-rated stocks. What is Forma Therapeutics' stock price forecast for 2022? 4 analysts have issued 12-month price targets for Forma Therapeutics' shares. Their FMTX stock forecasts range from $23.00 to $58.00. On average, they expect Forma Therapeutics' share price to reach $45.20 in the next year. This suggests a possible upside of 543.0% from the stock's current price. View analysts' price targets for Forma Therapeutics or view top-rated stocks among Wall Street analysts. How has Forma Therapeutics' stock performed in 2022? Forma Therapeutics' stock was trading at $14.22 on January 1st, 2022. Since then, FMTX shares have decreased by 50.6% and is now trading at $7.03. View the best growth stocks for 2022 here. When is Forma Therapeutics' next earnings date? Forma Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for Forma Therapeutics. How were Forma Therapeutics' earnings last quarter? Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) posted its quarterly earnings data on Friday, May, 6th. The company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.11. During the same period in the previous year, the company earned ($0.76) EPS. View Forma Therapeutics' earnings history. Who are Forma Therapeutics' key executives? Forma Therapeutics' management team includes the following people: Mr. Frank D. Lee, Pres, CEO & Director (Age 54, Pay $963.2k) (LinkedIn Profile)Mr. Todd E. Shegog, Sr. VP & CFO (Age 56, Pay $620.25k)Dr. Patrick F. Kelly M.D., Sr. VP & Chief Medical Officer (Age 57, Pay $636.58k) (LinkedIn Profile)Dr. John E. Bishop Ph.D., Sr. VP & Chief Technology Officer (Age 60)Dr. David N. Cook Ph.D., Sr. VP & Chief Scientific Officer (Age 64)Mr. Mario Vincent Corso C.F.A., Head of Investor RelationsDr. Jeannette Potts J.D., Ph.D., Sr. VP, Gen. Counsel & Corp. Sec. (Age 60) (LinkedIn Profile)Ms. Mary E. Wadlinger, Sr. VP of Corp. Affairs & Chief HR Officer (Age 62)Mr. Brian Lesser, Sr. VP of Commercial (Age 47)Dr. Ifeyinwa Osunkwo M.D., M.P.H., Sr. VP & Chief Patient Officer Who are some of Forma Therapeutics' key competitors? Some companies that are related to Forma Therapeutics include Sana Biotechnology (SANA), SpringWorks Therapeutics (SWTX), Adaptive Biotechnologies (ADPT), Vericel (VCEL), REGENXBIO (RGNX), Vaxcyte (PCVX), Kymera Therapeutics (KYMR), Editas Medicine (EDIT), Replimune Group (REPL), Alector (ALEC), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), iTeos Therapeutics (ITOS), Atara Biotherapeutics (ATRA) and Instil Bio (TIL). View all of FMTX's competitors. What other stocks do shareholders of Forma Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Forma Therapeutics investors own include Boeing (BA), Marvell Technology (MRVL), Trade Desk (TTD), Abbott Laboratories (ABT), CVS Health (CVS), Walt Disney (DIS), DocuSign (DOCU), Gilead Sciences (GILD), Intuit (INTU) and Neurocrine Biosciences (NBIX). When did Forma Therapeutics IPO? (FMTX) raised $201 million in an initial public offering on Friday, June 19th 2020. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. Jefferies' SVB Leerink and Credit Suisse acted as the underwriters for the IPO. What is Forma Therapeutics' stock symbol? Forma Therapeutics trades on the NASDAQ under the ticker symbol "FMTX." Who are Forma Therapeutics' major shareholders? Forma Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.37%), State Street Corp (5.91%), Vanguard Group Inc. (4.77%), Deep Track Capital LP (3.50%), Renaissance Technologies LLC (1.35%) and Northern Trust Corp (0.66%). Company insiders that own Forma Therapeutics stock include Frank D Lee, Jeannette Potts, Patrick F Kelly and Todd Shegog. View institutional ownership trends for Forma Therapeutics. Which major investors are selling Forma Therapeutics stock? FMTX stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Citigroup Inc., Goldman Sachs Group Inc., Charles Schwab Investment Management Inc., BlackRock Inc., California State Teachers Retirement System, ProShare Advisors LLC, and Bank of America Corp DE. Company insiders that have sold Forma Therapeutics company stock in the last two years include Frank D Lee, Jeannette Potts, Patrick F Kelly, and Todd Shegog. View insider buying and selling activity for Forma Therapeutics or view top insider-selling stocks. Which major investors are buying Forma Therapeutics stock? FMTX stock was bought by a variety of institutional investors in the last quarter, including Deep Track Capital LP, State Street Corp, Renaissance Technologies LLC, Silverarc Capital Management LLC, Bollard Group LLC, PDT Partners LLC, Qube Research & Technologies Ltd, and Invesco Ltd.. View insider buying and selling activity for Forma Therapeutics or or view top insider-buying stocks. How do I buy shares of Forma Therapeutics? Shares of FMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Forma Therapeutics' stock price today? One share of FMTX stock can currently be purchased for approximately $7.03. How much money does Forma Therapeutics make? Forma Therapeutics (NASDAQ:FMTX) has a market capitalization of $336.07 million and generates $100.56 million in revenue each year. The company earns $-172.96 million in net income (profit) each year or ($3.820010) on an earnings per share basis. How many employees does Forma Therapeutics have? Forma Therapeutics employs 166 workers across the globe. How can I contact Forma Therapeutics? Forma Therapeutics' mailing address is 500 ARSENAL STREET SUITE 100, WATERTOWN MA, 02472. The official website for Forma Therapeutics is www.formatherapeutics.com. The company can be reached via phone at 617-679-1970 or via email at [email protected]. This page (NASDAQ:FMTX) was last updated on 6/24/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here